Olink listed on Nasdaq
Summa Equity is pleased to announce that on 24 March 2021, portfolio company Olink, the proteomics platform, successfully priced its initial public offering of 17,647,058 American depositary shares (ADS), each representing one ordinary share, at a price of $20.00 per ADS. ADSs in Olink began trading on 25 March on the Nasdaq Global Market under the ticker symbol “OLK”. The offering closed on 29 March, after fulfilling customary closing conditions. The IPO raised $264.7 million in gross proceeds for Olink.
Olink Proteomics provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526 or by emailing Prospectusemail@example.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston Massachusetts 02110, telephone: 800-808-7525, ext. 6218 or by email at firstname.lastname@example.org.
This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.
Hannah G. Jacobsen, Director and Head of IR, Summa Equity
Mob: +47 936 41 960
Stina Thorman, IR Manager, Olink
Mob: +46 707 18 7354